Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

British Journal of Haematology

Volumn 169, Issue 4, 2015, Pages 506-519

  Frys, Sarah ^a   Simons, Zachary ^a   Hu, Qiang ^a   Barth, Matthew J ^a   Gu, Juan J ^a   Mavis, Cory ^a   Skitzki, Joseph ^a   Song, Liu ^a   Czuczman, Myron S ^a   Hernandez Ilizaliturri, Francisco J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Entinostat; Histone deacetylase inhibitors; Lymphoma; Rituximab

Indexed keywords

BORTEZOMIB; CASPASE; CD20 ANTIGEN; CELL ADHESION MOLECULE; CYTARABINE; ENTINOSTAT; PROTEIN BCL XL; PROTEIN P21; RITUXIMAB; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; BORONIC ACID DERIVATIVE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN BCL X; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; LYMPHOMA, B-CELL; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; BENZAMIDES; BORONIC ACIDS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; MICE, SCID; PYRAZINES; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928434641     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13318     Document Type: Article

References (52)

1. Abbas, T. & Dutta, A. (2009) p21 in cancer: intricate networks and multiple activities. Nature Reviews Cancer, 9, 400-414.
2. Bolden, J.E., Peart, M.J. & Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5, 769-784.
3. Brem, E.A., Thudium, K., Khubchandani, S., Tsai, P.C., Olejniczak, S.H., Bhat, S., Riaz, W., Gu, J., Iqbal, A., Campagna, R., Knight, J., Mavis, C., Hoskin, P., Deeb, G., Gibbs, J.F., Fetterly, G., Czuczman, M.S. & Hernandez-Ilizaliturri, F.J. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology, 153, 599-611.
4. Bryceson, Y.T., March, M.E., Barber, D.F., Ljunggren, H.G. & Long, E.O. (2005) Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. Journal of Experimental Medicine, 202, 1001-1012.
5. Buglio, D. & Younes, A. (2010) Histone deacetylase inhibitors in Hodgkin lymphoma. Investigational New Drugs, 28, S21-S27.
6. Buglio, D., Georgakis, G.V., Hanabuchi, S., Arima, K., Khaskhely, N.M., Liu, Y.J. & Younes, A. (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood, 112, 1424-1433.
7. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
8. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine, 6, 443-446.
9. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
10. Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippenstein, D., Dallaire, B. & Varns, C. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology, 17, 268-276.
11. Czuczman, M.S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J. & Hernandez-Ilizaliturri, F.J. (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research, 14, 1561-1570.
12. Dasmahapatra, G., Lembersky, D., Son, M.P., Attkisson, E., Dent, P., Fisher, R.I., Friedberg, J.W. & Grant, S. (2011) Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics, 10, 1686-1697.
13. DeAngelo, D.J., Spencer, A., Bhalla, K.N., Prince, H.M., Fischer, T., Kindler, T., Giles, F.J., Scott, J.W., Parker, K., Liu, A., Woo, M., Atadja, P., Mishra, K.K. & Ottmann, O.G. (2013) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia, 27, 1628-1636.
14. Eberle, F.C., Rodriguez-Canales, J., Wei, L., Hanson, J.C., Killian, J.K., Sun, H.W., Adams, L.G., Hewitt, S.M., Wilson, W.H., Pittaluga, S., Meltzer, P.S., Staudt, L.M., Emmert-Buck, M.R. & Jaffe, E.S. (2011) Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica, 96, 558-566.
15. Fandy, T.E., Herman, J.G., Kerns, P., Jiemjit, A., Sugar, E.A., Choi, S.H., Yang, A.S., Aucott, T., Dauses, T., Odchimar-Reissig, R., Licht, J., McConnell, M.J., Nasrallah, C., Kim, M.K., Zhang, W., Sun, Y., Murgo, A., Espinoza-Delgado, I., Oteiza, K., Owoeye, I., Silverman, L.R., Gore, S.D. & Carraway, H.E. (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood, 114, 2764-2773.
16. Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.P., Repp, R., Wandt, H., Pott, C., Seymour, J.F., Metzner, B., Hanel, A., Lehmann, T., Hartmann, F., Einsele, H. & Hiddemann, W. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 108, 4003-4008.
17. Fuchs, A. & Colonna, M. (2006) The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Seminars in Cancer Biology, 16, 359-366.
18. Glozak, M.A. & Seto, E. (2007) Histone deacetylases and cancer. Oncogene, 26, 5420-5432.
19. Gojo, I., Jiemjit, A., Trepel, J.B., Sparreboom, A., Figg, W.D., Rollins, S., Tidwell, M.L., Greer, J., Chung, E.J., Lee, M.J., Gore, S.D., Sausville, E.A., Zwiebel, J. & Karp, J.E. (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 109, 2781-2790.
20. Gross, C.C. (2010) Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization. Journal of Immunology, 185, 2918-2926.
21. Harrison, S.J., Bishton, M., Bates, S.E., Grant, S., Piekarz, R.L., Johnstone, R.W., Dai, Y., Lee, B., Araujo, M.E. & Prince, H.M. (2012) A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax((R))). Epigenomics, 4, 571-589.
22. Hatjiharissi, E., Hansen, M., Santos, D.D., Xu, L., Leleu, X., Dimmock, E.W., Ho, A.W., Hunter, Z.R., Branagan, A.R., Patterson, C.J., Kortsaris, A., Verselis, S., Fox, E. & Treon, S.P. (2007) Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clinical Lymphoma & Myeloma, 7, 286-290.
23. Hernandez-Ilizaliturri, F.J., Jupudy, V., Ostberg, J., Oflazoglu, E., Huberman, A., Repasky, E. & Czuczman, M.S. (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research, 9, 5866-5873.
24. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
25. Jona, A., Khaskhely, N., Buglio, D., Shafer, J.A., Derenzini, E., Bollard, C.M., Medeiros, L.J., Illes, A., Ji, Y. & Younes, A. (2011) The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental Hematology, 39, 1007-1017 e1001.
26. Kalac, M., Scotto, L., Marchi, E., Amengual, J., Seshan, V.E., Bhagat, G., Ulahannan, N., Leshchenko, V.V., Temkin, A.M., Parekh, S., Tycko, B. & O'Connor, O.A. (2011) HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood, 118, 5506-5516.
27. Kirschbaum, M., Frankel, P., Popplewell, L., Zain, J., Delioukina, M., Pullarkat, V., Matsuoka, D., Pulone, B., Rotter, A.J., Espinoza-Delgado, I., Nademanee, A., Forman, S.J., Gandara, D. & Newman, E. (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 29, 1198-1203.
28. Kirschbaum, M.H., Goldman, B.H., Zain, J.M., Cook, J.R., Rimsza, L.M., Forman, S.J. & Fisher, R.I. (2012) A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leukaemia & Lymphoma, 53, 259-262.
29. Kummar, S., Gutierrez, M., Gardner, E.R., Donovan, E., Hwang, K., Chung, E.J., Lee, M.J., Maynard, K., Kalnitskiy, M., Chen, A., Melillo, G., Ryan, Q.C., Conley, B., Figg, W.D., Trepel, J.B., Zwiebel, J., Doroshow, J.H. & Murgo, A.J. (2007) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clinical Cancer Research, 13, 5411-5417.
30. Lemoine, M., Derenzini, E., Buglio, D., Medeiros, L.J., Davis, R.E., Zhang, J., Ji, Y. & Younes, A. (2012) The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood, 119, 4017-4025.
31. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417-1423.
32. Miedema, F., Tetteroo, P.A., Hesselink, W.G., Werner, G., Spits, H. & Melief, C.J. (1984) Both Fc receptors and lymphocyte-function-associated antigen 1 on human T gamma lymphocytes are required for antibody-dependent cellular cytotoxicity (killer cell activity). European Journal of Immunology, 14, 518-523.
33. Minucci, S. & Pelicci, P.G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 6, 38-51.
34. Olejniczak, S.H., Hernandez-Ilizaliturri, F.J., Clements, J.L. & Czuczman, M.S. (2008) Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical Cancer Research, 14, 1550-1560.
35. Perez, O.D., Mitchell, D., Jager, G.C. & Nolan, G.P. (2004) LFA-1 signaling through p44/42 is coupled to perforin degranulation in CD56 + CD8 + natural killer cells. Blood, 104, 1083-1093.
36. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology, 7, 379-391.
37. Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H., Zain, J., Prince, H.M., Leonard, J.P., Geskin, L.J., Reeder, C., Joske, D., Figg, W.D., Gardner, E.R., Steinberg, S.M., Jaffe, E.S., Stetler-Stevenson, M., Lade, S., Fojo, A.T. & Bates, S.E. (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology, 27, 5410-5417.
38. Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M.A. & Rudek, M.A. (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. British Journal of Cancer, 106, 77-84.
39. Rosato, R.R., Almenara, J.A. & Grant, S. (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research, 63, 3637-3645.
40. Rudnicka, D., Oszmiana, A., Finch, D.K., Strickland, I., Schofield, D.J., Lowe, D.C., Sleeman, M.A. & Davis, D.M. (2013) Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood, 121, 4694-4702.
41. Ryan, Q.C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J.B., Ye, J., Figg, W.D., Hwang, K., Chung, E.J., Murgo, A., Melillo, G., Elsayed, Y., Monga, M., Kalnitskiy, M., Zwiebel, J. & Sausville, E.A. (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Journal of Clinical Oncology, 23, 3912-3922.
42. Shi, H., Guo, J., Duff, D.J., Rahmatpanah, F., Chitima-Matsiga, R., Al-Kuhlani, M., Taylor, K.H., Sjahputera, O., Andreski, M., Wooldridge, J.E. & Caldwell, C.W. (2007) Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis, 28, 60-70.
43. Shimizu, R., Kikuchi, J., Wada, T., Ozawa, K., Kano, Y. & Furukawa, Y. (2010) HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia, 24, 1760-1768.
44. Thieblemont, C., Briere, J., Mounier, N., Voelker, H.U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundstrom, C., Cogliatti, S., Trougouboff, P., Boudova, L., Ysebaert, L., Soulier, J., Chevalier, C., Bron, D., Schmitz, N., Gaulard, P., Houlgatte, R. & Gisselbrecht, C. (2011) The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. Journal of Clinical Oncology, 29, 4079-4087.
45. Tiffon, C., Adams, J., van der Fits, L., Wen, S., Townsend, P., Ganesan, A., Hodges, E., Vermeer, M. & Packham, G. (2011) The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. British Journal of Pharmacology, 162, 1590-1602.
46. Tsai, P.C., Hernandez-Ilizaliturri, F.J., Bangia, N., Olejniczak, S.H. & Czuczman, M.S. (2012) Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 18, 1039-1050.
47. Vilas-Zornoza, A., Agirre, X., Abizanda, G., Moreno, C., Segura, V., De Martino Rodriguez, A., Jose-Eneriz, E.S., Miranda, E., Martin-Subero, J.I., Garate, L., Blanco-Prieto, M.J., Garcia de Jalon, J.A., Rio, P., Rifon, J., Cigudosa, J.C., Martinez-Climent, J.A., Roman-Gomez, J., Calasanz, M.J., Ribera, J.M. & Prosper, F. (2012) Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia, 26, 1517-1526.
48. Wenzel, S.S., Grau, M., Mavis, C., Hailfinger, S., Wolf, A., Madle, H., Deeb, G., Dorken, B., Thome, M., Lenz, P., Dirnhofer, S., Hernandez-Ilizaliturri, F.J., Tzankov, A. & Lenz, G. (2013) MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia, 27, 1381-1390.
49. Witta, S.E., Jotte, R.M., Konduri, K., Neubauer, M.A., Spira, A.I., Ruxer, R.L., Varella-Garcia, M., Bunn, P.A. Jr & Hirsch, F.R. (2012) Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. Journal of Clinical Oncology, 30, 2248-2255.
50. Yardley, D.A., Ismail-Khan, R.R., Melichar, B., Lichinitser, M., Munster, P.N., Klein, P.M., Cruickshank, S., Miller, K.D., Lee, M.J. & Trepel, J.B. (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. Journal of Clinical Oncology, 31, 2128-2135.
51. Zain, J. (2012) Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma. Hematology/oncology Clinics of North America, 26, 671-704, ix.
52. Zhao, W.L., Wang, L., Liu, Y.H., Yan, J.S., Leboeuf, C., Liu, Y.Y., Wu, W.L., Janin, A., Chen, Z. & Chen, S.J. (2007) Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Experimental Hematology, 35, 1801-1811.